No... it is subsidizing. Developing drugs is expensive and high risk... there has to be a monetary mechanism to incentivize drug development and, right now, th

No... it is subsidizing. Developing drugs is expensive and high risk... there has to be a monetary mechanism to incentivize drug development and, right now, that is the promise of high profits, which mostly happens in the US. Therefore, US is carrying most of the incentivizing burden for pharma development. The rate of innovation would slip for global drug development without the promise of high prices and blockbuster profits in the US market. I have worked for a couple different Pharma companies, including those HQ'ed in Europe, and this is basically the situation. EU based Pharma companies make most of their profit in the US (almost every pharma company does). There are other ways to incentivize drug development and/or defray the financial risk of development, of course... but this is situation today... has been for a long time.